Clinical Trial

Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury

Completed
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to understand why liver transplants from donors with fatty liver disease (steatotic donor livers) are more vulnerable to post-transplant injury, analyzing historical clinical data and collected tissue samples using advanced genetic techniques. The main questions it aims to answer are: * Which specific cell types and their spatial interactions contribute to increased post-transplant injury susceptibility in steatotic donor livers? * What are the key molecular differences in gene expression between steatotic and normal donor livers following transplantation? Researchers will compare 300 historical liver transplant cases from 2015-2025, including 50 cases with archived tissue samples available for molecular analysis, and 250 cases with clinical data only. Donor liver steatosis was assessed by histopathology when tissue was available, or by donor clinical data when tissue was not available. The two groups (steatotic donor liver recipients vs. normal donor liver recipients) will be matched based on donor age, ischemia time, recipient scores, and other key clinical parameters to control for potential confounding variables. This is a retrospective analysis of existing data and archived biospecimens; no prospective participant enrollment or additional sample collection will occur.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Status change: Not Yet Recruiting → Completed 2026-02-03
Trial Details
NCT Number NCT07362745
Lead Sponsor Xijing Hospital
Conditions Fatty Liver, Liver Transplant; Complications, Ischaemia Reperfusion Injury of Liver, End Stage Liver Disease, Liver Failure, Postoperative Complications
Enrollment 300 participants
Start Date 2015-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-06